ARTICLE | Preclinical News
Boehringer joins KRAS race with a molecule designed to block all mutations
Boehringer’s pan-KRAS blocker could treat more patients than leading compounds against KRAS G12C
October 30, 2019 12:03 AM UTC
Updated on Oct 31, 2019 at 11:51 PM UTC
Boehringer announced Tuesday that its SOS1:KRAS inhibitor BI 1701963 started Phase I testing, making it the latest company to enter the clinic with a KRAS inhibitor.
Unlike the Phase I/II molecules from Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc. (NASDAQ:MRTX) that selectively target the common KRAS G12C mutation, Boehringer Ingelheim GmbH’s molecule is designed to block signaling of all KRAS mutations...